Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Se Young | - |
dc.contributor.author | Kim, Yunlim | - |
dc.contributor.author | Lim, Bumjin | - |
dc.contributor.author | Wee, Chung Beum | - |
dc.contributor.author | Chang, In Ho | - |
dc.contributor.author | Kim, Choung-Soo | - |
dc.date.accessioned | 2024-05-20T07:35:15Z | - |
dc.date.available | 2024-05-20T07:35:15Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73779 | - |
dc.description.abstract | Purpose: We developed immune checkpoint molecules to target recombinant dendritic cells (DCs) and verified their anti-tumor efficacy and immune response against prostate cancer. Materials and Methods: DCs were generated from mononuclear cells in the tibia and femur bone marrow of mice. We knocked down the programmed death ligand 1 (PD-L1) on monocyte-derived DCs through siRNA PD-L1. Cell surface antigens were immune fluorescently stained through flow cytometry to analyze cultured cell phenotypes. Furthermore, we evaluated the efficacy of monocyte-derived DCs and recombinant DCs in a prostate cancer mouse model with subcutaneous TRAMP-C1 cells. Lastly, DC-induced mixed lymphocyte and lymphocyte-only proliferations were compared to determine cultured DCs'function. Results: Compared to the control group, siRNA PD-L1 therapeutic DC-treated mice exhibited significantly inhibited tumor volume and increased tumor cell apoptosis. Remarkably, this treatment substantially augmented interferon-gamma and interleukin-2 production by stimulating T-cells in an allogeneic mixed lymphocyte reaction. Moreover, we demonstrated that PD-L1 gene silencing improved cell proliferation and cytokine production. Conclusions: We developed monocyte-derived DCs transfected with PD-L1 siRNA from mouse bone marrow. Our study highlights that PD-L1 inhibition in DCs increases antigen-specific immune responses, corroborating previous immunotherapy methodology findings regarding castration-resistant prostate cancer. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN UROLOGICAL ASSOC | - |
dc.title | Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.20230348 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, v.65, no.3, pp 300 - 310 | - |
dc.identifier.kciid | ART003078317 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001208063200001 | - |
dc.identifier.scopusid | 2-s2.0-85192614812 | - |
dc.citation.endPage | 310 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 300 | - |
dc.citation.title | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.volume | 65 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Dendritic cell | - |
dc.subject.keywordAuthor | Immune tolerance | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Prostate cancer | - |
dc.subject.keywordPlus | I CLINICAL-TRIAL | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | MATURATION | - |
dc.subject.keywordPlus | IPILIMUMAB | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.